CAMBRIDGE, Mass.--Millennium Pharmaceuticals and Bayer announced that they have identified 18 novel drug targets and moved four of them into high-throughput screening in less than eight months. In the collaboration, which is taking a production-oriented approach based on genomics research to move compounds toward clinical trials, targets were identified and validated by Millennium and are being screened by Bayer.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.